{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:47:59Z","timestamp":1773078479239,"version":"3.50.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AI112393"],"award-info":[{"award-number":["K24AI112393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.cjca.2018.12.024","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T22:55:30Z","timestamp":1546037730000},"page":"238-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Mechanisms of Cardiovascular Disease in the Setting of HIV Infection"],"prefix":"10.1016","volume":"35","author":[{"given":"Priscilla Y.","family":"Hsue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2018.12.024_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.cjca.2018.12.024_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciu261","article-title":"Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients","volume":"59","author":"Ingle","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/0140-6736(90)90531-9","article-title":"Pericardial effusion and HIV infection","volume":"335","author":"Taelman","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.12.024_bib4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0735-1097(10)80134-2","article-title":"Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study","volume":"17","author":"Blanchard","year":"1991","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.12.024_bib5","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1161\/01.CIR.92.11.3229","article-title":"Pericardial effusion in AIDS: incidence and survival","volume":"92","author":"Heidenreich","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.12.024_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/1054-8807(92)90042-M","article-title":"Dilated cardiomyopathy in a zidovudine-treated AIDS patient","volume":"1","author":"d'Amati","year":"1992","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.cjca.2018.12.024_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/hrt.76.2.161","article-title":"Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe","volume":"76","author":"Hakim","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2018.12.024_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-116-4-311","article-title":"Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases","volume":"116","author":"Herskowitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/01.RES.74.2.344","article-title":"Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine","volume":"74","author":"Lewis","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2018.12.024_bib10","first-page":"207","article-title":"Pericarditis and acquired immunodeficiency syndrome","volume":"81","author":"Malu","year":"1988","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.cjca.2018.12.024_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(98)00022-1","article-title":"Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities","volume":"352","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.12.024_bib12","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/S0140-6736(98)26026-0","article-title":"Vascular complications associated with use of HIV protease inhibitors","volume":"351","author":"Behrens","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.12.024_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/CIRCULATIONAHA.117.032647","article-title":"Association of human immunodeficiency virus infection and risk of peripheral artery disease","volume":"138","author":"Beckman","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.12.024_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamacardio.2017.0264","article-title":"Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study","volume":"2","author":"Freiberg","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2018.12.024_bib16","first-page":"249","article-title":"Lipid abnormalities in persons living with HIV infection","volume":"35","author":"Waters","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.12.024_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jash.2015.03.008","article-title":"Hypertension\u2014an emerging cardiovascular risk factor in HIV infection","volume":"9","author":"Antonello","year":"2015","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.cjca.2018.12.024_bib18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/cid\/civ013","article-title":"Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking","volume":"60","author":"Rasmussen","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11904-014-0219-7","article-title":"Metabolic syndrome, diabetes, and cardiovascular risk in HIV","volume":"11","author":"Nix","year":"2014","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.cjca.2018.12.024_bib20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/QAD.0000000000001967","article-title":"Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort","volume":"32","author":"Pelchen-Matthews","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with the human immunodeficiency virus: a systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.12.024_bib22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCULATIONAHA.118.036211","article-title":"Time to recognize HIV infection as a major cardiovascular risk factor","volume":"138","author":"Hsue","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.12.024_bib23","doi-asserted-by":"crossref","first-page":"e004312","DOI":"10.1161\/CIRCHEARTFAILURE.117.004312","article-title":"Association of biomarker clusters with cardiac phenotypes and mortality in patients with HIV infection","volume":"11","author":"Scherzer","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2018.12.024_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12981-016-0103-1","article-title":"Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection","volume":"13","author":"Tincati","year":"2016","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.cjca.2018.12.024_bib25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.chom.2016.02.011","article-title":"Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome","volume":"19","author":"Monaco","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cjca.2018.12.024_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/mi.2013.116","article-title":"An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia","volume":"7","author":"Dillon","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.cjca.2018.12.024_bib28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib29","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","article-title":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis","volume":"38","author":"Schiattarella","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.12.024_bib30","doi-asserted-by":"crossref","first-page":"e004947","DOI":"10.1161\/JAHA.116.004947","article-title":"Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies","volume":"6","author":"Heianza","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hfc.2017.08.011","article-title":"Metabolic biomarkers in heart failure","volume":"14","author":"Albert","year":"2018","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cjca.2018.12.024_bib32","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/infdis\/jiy356","article-title":"Gut microbial-related choline metabolite trimethylamine-N-oxide is associated with progression of carotid artery atherosclerosis in HIV infection","volume":"218","author":"Shan","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/QAD.0000000000000565","article-title":"Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine","volume":"29","author":"Srinivasa","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/QAI.0000000000000937","article-title":"Brief report: intestinal microbiota-produced trimethylamine-N-oxide and its association with coronary stenosis and HIV serostatus","volume":"72","author":"Miller","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.12.024_bib35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/infdis\/jiu305","article-title":"Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection","volume":"210","author":"Sandler","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiu515","article-title":"Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy\u2014ACTG A5286","volume":"211","author":"Tenorio","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/QAI.0000000000001693","article-title":"Effect of Lactobacillus rhamnosus GG supplementation on intestinal inflammation assessed by PET\/MRI scans and gut microbiota composition in HIV-infected individuals","volume":"78","author":"Arnbjerg","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.12.024_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116306","article-title":"The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial","volume":"9","author":"Somsouk","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cjca.2018.12.024_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1255512","article-title":"Immunologic strategies for HIV-1 remission and eradication","volume":"345","author":"Barouch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.cjca.2018.12.024_bib40","first-page":"157","article-title":"Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART)","volume":"4","author":"Valdez","year":"2002","journal-title":"AIDS Rev"},{"key":"10.1016\/j.cjca.2018.12.024_bib41","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T\u00a0cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy","volume":"187","author":"Hunt","year":"2003","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib42","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib43","doi-asserted-by":"crossref","first-page":"e004243","DOI":"10.1161\/JAHA.116.004243","article-title":"Role of T-cell dysfunction, inflammation, and coagulation in microvascular disease in HIV","volume":"5","author":"Sinha","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008886","article-title":"Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease","volume":"5","author":"Naeger","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.cjca.2018.12.024_bib45","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1097\/QAD.0b013e3280108704","article-title":"Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses","volume":"20","author":"Hsue","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib46","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/infdis\/jis276","article-title":"Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women","volume":"205","author":"Parrinello","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib47","doi-asserted-by":"crossref","first-page":"e005025","DOI":"10.1161\/JAHA.116.005025","article-title":"Cytomegalovirus infection and relative risk of cardiovascular disease (ischemic heart disease, stroke, and cardiovascular death): a meta-analysis of prospective studies up to 2016","volume":"6","author":"Wang","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib48","doi-asserted-by":"crossref","first-page":"682","DOI":"10.12659\/AOT.905267","article-title":"Heart transplantation and risk of cardiac vasculopathy development: what factors are important?","volume":"22","author":"Sobieszczanska-Malek","year":"2017","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cjca.2018.12.024_bib49","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/01.CIR.0000124480.32233.8A","article-title":"Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection","volume":"109","author":"Hsue","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.12.024_bib50","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/QAD.0b013e328352ce54","article-title":"The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease","volume":"26","author":"Ho","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib51","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/cid\/ciw615","article-title":"Cardiovascular disease risk prediction in the HIV outpatient study","volume":"63","author":"Thompson-Paul","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/QAI.0b013e3181f4b752","article-title":"Association of immunologic and virologic factors with myocardial infarction rates in a US health care system","volume":"55","author":"Triant","year":"2010","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.12.024_bib53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/QAI.0000000000001450","article-title":"Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population","volume":"75","author":"Drozd","year":"2017","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.12.024_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cjca.2018.12.024_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085798","article-title":"Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio","volume":"9","author":"Serrano-Villar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2018.12.024_bib56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/cix466","article-title":"CD4: CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the Antiretroviral Therapy Cohort Collaboration (ART-CC)","volume":"65","author":"Trickey","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib57","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection","volume":"348","author":"Bozzette","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib58","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib59","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Group","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib60","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"Kuller","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib62","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib63","doi-asserted-by":"crossref","first-page":"ofw213","DOI":"10.1093\/ofid\/ofw213","article-title":"Early antiretroviral therapy at high CD4 counts does not improve arterial elasticity: a substudy of the Strategic Timing of AntiRetroviral Treatment (START) trial","volume":"3","author":"Baker","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib64","doi-asserted-by":"crossref","first-page":"e004987","DOI":"10.1161\/JAHA.116.004987","article-title":"Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial","volume":"6","author":"Baker","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib65","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.12.024_bib66","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","article-title":"Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data","volume":"25","author":"Cruciani","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib67","doi-asserted-by":"crossref","first-page":"ofy086","DOI":"10.1093\/ofid\/ofy086","article-title":"Abacavir use and risk for myocardial infarction and cardiovascular events: pooled analysis of data from clinical trials","volume":"5","author":"Nan","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib68","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0000000000001547","article-title":"Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation","volume":"31","author":"Alvarez","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib69","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/infdis\/jir509","article-title":"Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy","volume":"204","author":"Satchell","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib70","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1097\/QAD.0b013e32832e7140","article-title":"Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients","volume":"23","author":"Hsue","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib71","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000000762","article-title":"A\u00a0prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness: AIDS Clinical Trial Group Study A5260s","volume":"29","author":"Stein","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib72","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study","volume":"5","author":"Ryom","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cjca.2018.12.024_bib73","doi-asserted-by":"crossref","first-page":"e007792","DOI":"10.1161\/JAHA.117.007792","article-title":"Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (Veterans Aging Cohort Study)","volume":"7","author":"Marconi","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/15284336.2018.1455366","article-title":"The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients","volume":"19","author":"Krikke","year":"2018","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.cjca.2018.12.024_bib75","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib76","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2018.04.083","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure","volume":"72","author":"Alvi","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.12.024_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044454","article-title":"Inflammation, coagulation and cardiovascular disease in HIV-infected individuals","volume":"7","author":"Duprez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2018.12.024_bib78","article-title":"Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation","volume":"3","author":"Nordell","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155100","article-title":"Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy","volume":"11","author":"Grund","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.cjca.2018.12.024_bib80","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/QAD.0000000000001515","article-title":"Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers","volume":"31","author":"Kim","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib81","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/QAI.0b013e31826e7d0f","article-title":"A\u00a0randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection","volume":"61","author":"Hatano","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.12.024_bib82","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib83","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.12.024_bib84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.12.024_bib85","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.12.024_bib86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib87","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cjca.2018.12.024_bib88","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/infdis\/jiu012","article-title":"Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy","volume":"209","author":"Eckard","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib89","doi-asserted-by":"crossref","first-page":"ofw278","DOI":"10.1093\/ofid\/ofw278","article-title":"A\u00a0randomized placebo controlled trial of aspirin effects on immune activation in chronically human immunodeficiency virus-infected adults on virologically suppressive antiretroviral therapy","volume":"4","author":"O'Brien","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib90","article-title":"Safety and impact of low-dose methotrexate on endothelial function and inflammation in individuals with treated human immunodeficiency virus: AIDS Clinical Trial Group Study A5314 [Epub ahead of print]","author":"Hsue","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.12.024_bib91","unstructured":"Stein JH, Yeh E, Weber JM, et\u00a0al. Brachial artery echogenicity and grayscale texture changes in HIV-infected individuals receiving low-dose methotrexate: AIDS Clinical Trial Group Study. Arterioscler Thromb Vasc Biol, in press."},{"key":"10.1016\/j.cjca.2018.12.024_bib92","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events [Epub ahead of print]","author":"Ridker","year":"2018","journal-title":"N\u00a0Engl J\u00a0Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib93","unstructured":"Hsue PY, Li D, Weigal B, et\u00a0al. Relationship between leukopoietic activity and arterial inflammation in HIV: effects of IL-1\u03b2 inhibition. J\u00a0Am Coll Cardiol, in press."},{"key":"10.1016\/j.cjca.2018.12.024_bib94","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nri2956","article-title":"Platelets and the immune continuum","volume":"11","author":"Semple","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cjca.2018.12.024_bib95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjh.14653","article-title":"Platelets: much more than bricks in a breached wall","volume":"178","author":"Mancuso","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2018.12.024_bib96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00018-009-0209-x","article-title":"Platelets and viruses: an ambivalent relationship","volume":"67","author":"Flaujac","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cjca.2018.12.024_bib97","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11239-015-1212-8","article-title":"Platelet leukocyte aggregates and markers of platelet aggregation, immune activation and disease progression in HIV infected treatment naive asymptomatic individuals","volume":"40","author":"Nkambule","year":"2015","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.cjca.2018.12.024_bib98","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2014-05-572875","article-title":"Platelets: crossroads of immunity and hemostasis","volume":"124","author":"Jenne","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2018.12.024_bib99","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fimmu.2014.00649","article-title":"Platelets and infection\u2014an emerging role of platelets in viral infection","volume":"5","author":"Assinger","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.cjca.2018.12.024_bib100","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.4049\/jimmunol.1300354","article-title":"Lipopolysaccharide stimulates platelets through an IL-1\u03b2 autocrine loop","volume":"191","author":"Brown","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cjca.2018.12.024_bib101","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2011.11.022","article-title":"Endothelial and platelet function alterations in HIV-infected patients","volume":"129","author":"Gresele","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.cjca.2018.12.024_bib102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jacbts.2017.10.005","article-title":"Platelet transcriptome profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a mediator of platelet activity","volume":"3","author":"Marcantoni","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2018.12.024_bib103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.07.003","article-title":"The HIV protease inhibitor, ritonavir, dysregulates human platelet function in\u00a0vitro","volume":"169","author":"Loelius","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.cjca.2018.12.024_bib104","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1097\/QAD.0000000000000415","article-title":"Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen","volume":"28","author":"Tunjungputri","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib105","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1097\/QAD.0000000000001993","article-title":"A\u00a0switch to a raltegravir containing regimen does not lower platelet reactivity in HIV-infected individuals","volume":"32","author":"van der Heijden","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3851\/IMP2681","article-title":"Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study","volume":"19","author":"Wohl","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cjca.2018.12.024_bib107","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcmg.2013.08.019","article-title":"Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?","volume":"7","author":"Stein","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2018.12.024_bib108","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2018.05.001","article-title":"Evaluation of coronary features of HIV patients presenting with ACS: the CUORE, a multicenter study","volume":"274","author":"Peyracchia","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2018.12.024_bib109","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/M13-1754","article-title":"Associations between HIV infection and subclinical coronary atherosclerosis","volume":"160","author":"Post","year":"2014","journal-title":"Ann Int Med"},{"key":"10.1016\/j.cjca.2018.12.024_bib110","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/hrt.2009.177774","article-title":"HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies","volume":"95","author":"Hulten","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2018.12.024_bib111","doi-asserted-by":"crossref","first-page":"e000422","DOI":"10.1161\/JAHA.111.000422","article-title":"Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation","volume":"1","author":"Hsue","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.12.024_bib112","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1097\/QAD.0000000000001972","article-title":"Carotid artery atherosclerosis is associated with mortality in HIV-positive women and men","volume":"32","author":"Hanna","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib113","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1097\/QAD.0000000000001149","article-title":"Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy","volume":"30","author":"Hsu","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.12.024_bib114","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2012.6698","article-title":"Arterial inflammation in patients with HIV","volume":"308","author":"Subramanian","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.12.024_bib115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.4728","article-title":"Association of arterial and lymph node inflammation with distinct inflammatory pathways in human immunodeficiency virus infection","volume":"2","author":"Tawakol","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2018.12.024_bib116","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jacc.2008.04.049","article-title":"Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s","volume":"52","author":"Torriani","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.12.024_bib117","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/CIRCULATIONAHA.113.001719","article-title":"Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients","volume":"128","author":"Holloway","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.12.024_bib118","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.004430","article-title":"HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema","volume":"9","author":"Ntusi","year":"2016","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X18313862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X18313862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:40:29Z","timestamp":1760107229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X18313862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0828282X18313862"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2018.12.024","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Cardiovascular Disease in the Setting of HIV Infection","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2018.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}